Geurts-Moespot J, Leake R, Benraad T J, Sweep C G
Department of Chemical Endocrinology, University Hospital Nijmegen St. Radboud, The Netherlands.
Int J Oncol. 2000 Jul;17(1):13-22. doi: 10.3892/ijo.17.1.13.
Estrogen receptor (ER) assays have clinical relevance in selecting women who would benefit from endocrine intervention. As the degree of benefit from endocrine therapy is directly related to the quantity of receptor present in the tumour, the quality of the steroid receptor assays is important. Moreover, since patients entered in multi-centre trials often include stratification based on the receptor status, receptor assays should be comparable between different institutes. ER- and progesterone receptor (PgR)-assays have been evaluated in quality assessment studies for almost 20 years by the EORTC Receptor and Biomarker Study Group. This study analyses our findings over these years and concludes with a recommended minimum structure on which QA schemes for any biomarker could be based.
雌激素受体（ER）检测在选择能从内分泌干预中获益的女性患者方面具有临床意义。由于内分泌治疗的获益程度与肿瘤中存在的受体数量直接相关，类固醇受体检测的质量很重要。此外，由于参与多中心试验的患者通常根据受体状态进行分层，不同机构之间的受体检测应该具有可比性。欧洲癌症研究与治疗组织（EORTC）受体与生物标志物研究组在近20年的质量评估研究中对ER和孕激素受体（PgR）检测进行了评估。本研究分析了这些年来我们的研究结果，并得出了一个推荐的最低结构，任何生物标志物的质量保证方案都可以基于此结构。
